Gilead Sciences Inc drugs
24 results
Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate)
(efavirenz, emtricitabine, and tenofovir disoproxil fumarate)Gilead Sciences Inc
Usage: ATRIPLA® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen or in combination with other antiretroviral agents.
Atripla access (efavirenz, emtricitabine, and tenofovir disoproxil fumarate)
(EFAVIRENZ, EMTRICITABINE, and TENOFOVIR DISOPROXIL FUMARATE)Gilead Sciences Inc
Usage: ATRIPLA™ is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen or in combination with other antiretroviral agents.
Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
(bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)Gilead Sciences Inc
Usage: BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those without prior antiretroviral treatment history or to replace a stable regimen in virologically-suppressed patients without known resistance.
Complera (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
(emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)Gilead Sciences Inc
Usage: COMPLERA® is indicated for treating HIV-1 in adults and pediatric patients (≥35 kg) as initial therapy for those with HIV-1 RNA ≤100,000 copies/mL or to replace a stable regimen in virologically suppressed patients (HIV-1 RNA <50 copies/mL) without known drug resistance.
Complera access (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
(EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, and TENOFOVIR DISOPROXIL FUMARATE)Gilead Sciences Inc
Usage: COMPLERA™ is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg), either as initial therapy for those with baseline HIV-1 RNA ≤100,000 copies/mL or to replace a stable regimen in patients who are virologically suppressed with no treatment failures.
Descovy (emtricitabine and tenofovir alafenamide)
(emtricitabine and tenofovir alafenamide)Gilead Sciences Inc
Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg with other antiretrovirals; 14-35 kg excluding protease inhibitors). It is also used for pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
Emtriva (emtricitabine)
(EMTRICITABINE)Gilead Sciences Inc
Usage: EMTRIVA® is indicated for the treatment of HIV-1 infection, used in combination with other antiretroviral agents.
Epclusa access (velpatasvir and sofosbuvir)
(Velpatasvir and Sofosbuvir)Gilead Sciences Inc
Usage: EPCLUSA™ is indicated for treating chronic hepatitis C virus (HCV) infections in adults and pediatric patients aged 6 years and older, with specific genotypes (1-6). It is effective for those without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for decompensated cirrhosis cases.
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
(elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)Gilead Sciences Inc
Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg. It is used as a complete regimen for treatment-naive patients or to replace the current regimen in virologically-suppressed individuals with specific criteria.
Harvoni access (ledipasvir and sofosbuvir)
(LEDIPASVIR and SOFOSBUVIR)Gilead Sciences Inc
Usage: HARVONI is indicated for treating chronic hepatitis C virus (HCV) in adults and pediatric patients (≥12 years) with genotypes 1, 4, 5, or 6, including those without cirrhosis or with compensated cirrhosis, and certain cases involving decompensated cirrhosis or liver transplant recipients.